A clinical trial to compare the quality of life of HIV+ patients who start monotherapy with LPV/r versus continuing triple therapy with a boosted PI Pasquau, J*; Hidalgo, C; Vergara, A; Montes, M; Vergas, J; Sanjoaquín, I; Hernández-Quero, J; Aguirrebengoa, K; Orihuela, F; Rodríguez-Baño, J; Imaz, A; García-Vallecillos, C (Granada, Spain) P303 STRike -characteristics of HIV-1-infected patients treated with a single-tablet regimen in daily clinical practice Esser, S; Heiken, H; Gallo, L; Schellberg, S*; Schlag, M; Moll, A; Pauli, R; Stoehr, A; Degen, O; Jaeger, H; Stephan, C; Fätkenheuer, G (Martinsried, Germany) 
In previous studies of protease inhibitor (PI) monotherapy, the inclusion criteria for most clinical trials of PI monotherapy (switch studies) have included:
1. No history of virological failure on PI treatment 2. On stable HAART for 3-6 monthsCD4 nadir above 100-200 cells/uL (not in MOST or OK-04 trials)
In other PI monotherapy trials, the predictors of HIV RNA suppression were:
OK-04 trial -low nadir CD4 count, poor adherence, low baseline haemoglobin MOST trial-low nadir CD4 count Abbott 613 trial -low self-reported adherence and low baseline CD4 count MONOI trial -low nadir CD4 count, high pretreatment HIV RNA, higher baseline HIV DNA, baseline HIV RNA>1 copy/mL Kalesolo trial -older age
In addition, HCV co-infection is associated with lower HIV RNA suppression rates in a large meta-analysis (Pulido et al, AIDS Reviews 2012, Vol 14).
The Roche COBAS Amplicor assay produces two types of result when the HIV RNA concentration is <50 copies/mL: 1. No HIV RNA detected (Optical density = background): <5 copies/mL 2. Traces of HIV RNA detected (5-50 copies/mL) During first-line treatment, there is a progressive increase over time in the percentage of patients with HIV RNA <50 copies/mL and no detectable HIV RNA (e.g. ARTEMIS trial)
The objective of this analysis was to identify predictors of long-term HIV RNA suppression in the MONET trial. In this trial, 256 patients with HIV RNA <50 copies/mL at screening switched to DRV/r 800/100 mg once daily, either as monotherapy (n=127) or with 2NRTIs (n=129). Entry criteria included CD4 nadir above 100 cells/mm 3 and no history of virological failure. Hepatitis C co-infection was assessed by serology at baseline. HIV RNA was tested by the Roche COBAS Amplicor Assay. HIV RNA results were classified as either <5 (no detection), 5-49 (virus detected under quantification limit) or ≥50 copies/mL. Treatment failure was defined as two consecutive HIV RNA levels ≥50 copies/mL (TLOVR) by Week 144, or discontinuation of study drugs.
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Statistical Methods Results Conclusions
Multivariate logistic regression was used to identify factors predictive of treatment failure by Week 144:
• Age • Sex • Weight • Previous PI use • Hepatitis C antibody status • Baseline CD4 count • Nadir CD4 count • Baseline HIV RNA <5 copies/mL
This analysis was conducted for the primary ITT Switch=Failure population. Additional analyses were conducted (i) for the Per Protocol Population (ii) excluding discontinuations for adverse events or other reasons (iii) including patients who intensified with NRTIs.
By Week 144, HIV RNA <50 copies/mL (ITT, TLOVR, Switch=Failure) was 69% versus 75% in the DRV/r monotherapy and triple therapy arms respectively.
In the Switch Included analysis, HIV RNA <50 copies/mL was 84.0% versus 83.5% in the DRV/r monotherapy and triple therapy arms respectively In the multivariate analysis for the TLOVR endpoint, positive HCV serology correlated with treatment failure (Odds Ratio (OR) = 2.44, 95% CI 1.20-5.00).
In the analysis including only virological endpoints, both positive HCV serology (OR=2.77, (95% CI 1.18-6.67) and baseline HIV RNA >5 copies/mL (OR=2.71, 95% CI 1.21-6.08) predicted treatment failure.
In the Switch Included analysis, only HIV RNA >5 copies/mL was predictive of treatment failure (OR=2.78, 95% CI 1.28-6.01).
• However, despite the great success of highly active antiretroviral therapy (HAART), triple therapy (TT) regimens are associated to long-term toxicity, high costs, and a complex administration that may have direct consequences for HIV-infected patients because of a decreased treatment adherence, treatment dissatisfaction, the negative impact caused on Quality of Life (QoL), and above all because it could affect treatment efficacy 2-6 .
• Since over the past years LPV/r-MT as simplification strategy has proved to be non-inferior to TT in virological and immunological efficacy [7] [8] [9] . In Spain, use of simplification to LPV/r-MT has been included since January 2008 in treatment guidelines as a therapeutic option for patients with no history of prior protease inhibitor (PI) failure, an undetectable viral load (VL <50 cop/mL) for at least 6 months, and signs and/or symptoms of toxicity from Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 10 .
OBJECTIVE AND DESIGN OBJECTIVE AND DESIGN
• Primary objective was to compare the QoL of patients who start LPV/r-MT tablets versus patients continuing on TT containing any boosted protease inhibitor (bPI-TT) during the first 6 months of LPV/r-MT.
• Secondary objectives were to assess and compare LPV/r-MT versus bPI-TT on:
• 
METHODS METHODS

POPULATION POPULATION
Main inclusion criteria:
• HIV-1-infected patients infected, males or females aged ≥ 18 years, on antiretroviral TT containing any bPI.
• Undetectable viral load, defined as < 50 copies/mL of HIV RNA in the past 6 months.
• Written informed consent before any study-specific screening procedure.
Main exclusion criteria:
• Documented genotyping resistance of mutations that confers loss of susceptibility to LPV/r. Or evidence of having failed to therapy with PI.
• CD4 cell nadir <100 cells/μL.
• Impossibility to be treated with LPV/r.
• History of psychiatric disorders such as depressive syndrome, schizophrenia, or psychotic disease.
• Known history of drug addiction or chronic alcohol consumption • Pregnant or nursing women or women.
• Current active opportunistic infection or documented infection within 4 weeks of screening.
• Renal disease with creatinine clearance < 60 mL/min.
• Concomitant use of drugs contraindicated with LPV/r • Patients with acute hepatitis.
•Any disease that, in the investigator's judgment, contraindicates patient participation in the study. 35-item self-administered questionnaire to assess 11-related item to QoL The mental health summary score (MHSS) and physical health summary score (PHSS) were also calculated. 0 the worst health perception and 100 the best health perception.
DOMAIN
-Day 1 -Week 24 -Early discontinuati on visit EuroQol questionnaire (EQ-5D) 13 Five-dimensional items self-administered questionnaire. 0 the worst health perception and 100 the best health perception. Self-administered Simplified Medication Adherence Questionnaire which includes 6 items about: multidimensional adherence measurements versus missed-dose measurements; the classification of adherence as a dichotomy (adherent/non-adherent) variable; and the time interval evaluated (weeks versus days).
Visual analog scale (VAS) 15
Self-report that obtains a patient's subjective evaluation of his or her own level of treatment compliance behavior and classifies of adherence as a continuum variable. 0 the worst health perception and 100 the best health perception. • No statistical differences were observed when the five dimensions of the EQ-5D questionnaire were evaluated separately. The patients' answer distribution per item was similar between LPV/r-MT and bPI-TT arms (p-values no significant).
• There were no statistical differences when all the items of the MOS-HIV were analyzed separately. # The SMAQ was considered `positive' when a non-adherent patient was detected, that is, when there was a positive response to any of the qualitative questions, more than two doses missed over the past week, or over 2 days of total non-medication since the last visit. • When all the items included in the GEEMA questionnaire were analyzed separately, there were only statistical differences observed in the number of missed doses in the previous week (see table above).
• High adherence rates were found in both LPV/r-based regimens.
• The most common reasons for not taking the ARVs were similar in both arms, mainly for forgetting the doses (LPV/r-MT: 12.3% vs bPI-TT: 12.0%, p=1.0), no reason (LPV/r-MT: 13.7% vs bPI-TT: 8.0%, p=0.273) or other (LPV/r-MT: 5.5% vs bPI-TT: 12.0%, p=0.109). 
CONCLUSIONS CONCLUSIONS
• There were no statistical differences in the QoL in patients treated with LPV/r-MT or bPI-TT after 6 months of follow-up. All patients reported high QoL-related scores, independently if self-administered questionnaires were analyzed as a total score or as separately items.
• There were no statistical differences when adherence was evaluated using two different self-reported questionnaires or when reasons for not taking the ARVs were analyzed between both treatment groups. However, high rates of adherence were observed in all patients included. Moreover, no differences were found regarding treatment satisfaction.
• There was only observed a statistical difference in the number of missed doses in the previous week to study visit, since a higher proportion on patients in the bPI-TT arm reported more number of missed doses than patients treated with LPV/r-MT.
• The life-long antiretroviral treatment of HIV-1 infection requires effective • and well tolerated medications complemented by high rates of adherence in order to achieve viral suppression, immunologic reconstitution and to prevent the development of resistance Single Tablet Regimens (STR), combining a full antiretroviral regimen • in one tablet, taken once daily have been designed to achieve high adherence and better long-term outcomes "STRike" is the fi rst cohort study, describing the use of various STRs fi rst cohort study, describing the use of various STRs fi • in routine clinical practice in Germany, representing a country with predominantly offi ce-based HIV care fi ce-based HIV care fi
In this non-interventional observational cohort study 800 participants will be • included in 4 treatment arms Patients will be treated with the STRs TDF/FTC/EFV (one retrospective/ • prospective arm and one purely prospective arm), TDF/FTC/RPV or -after regulatory approval-with TDF/FTC/COBI/EVG Patients are followed prospectively for at least two years, and reasons for 
Regimen Prior to TDF/FTC/EFV
The vast majority (83.6%) of total pre-treated patients on TDF/FTC/EFV • (n=347) were switching from an NNRTI-regimen. Most common backbone was TDF/FTC (85%), accompanied by EFV (98%) (Fig. 3 ) Only 10.4% switched from an PI-regimen. TDF/FTC was backbone in 81% • of those patients, most commonly used PIs were LPV (56%) and DRV (28%) (Fig. 3) 6.1% of patients had been on various other ART regimens like • INI-regimen, double-NUC, triple-NUC, quadruple-NUC, PI-mono, double-PI, NUC+PI+NNRTI, or on therapy pause
Regimen Prior to TDF/FTC/RPV
Of the pretreated patients on TDF/FTC/RPV (n=56), many switched from • an NNRTI-regimen (44.6%) mostly consisting of TDF/FTC (96%) and EFV (72%) (Fig. 4) The percentage switching from a PI-regimen was higher in Arm 3 (28.6%) • The PI regimens consisted mostly of TDF/FTC (87%) combined with DRV (44%) or LPV (25%) (Fig. 4 
INTRODUCTION INTRODUCTION INTRODUCTION
METHODS
METHODS METHODS
•Strategies aimed to prevent toxicity derived from long-term exposure to NRTI are desirable for the management of HIV-infected patients.
•Monotherapy with boosted protease inhibitors (PIs) as simplified NRTIsparing regimen has gained interest in the recent years. PI monotherapy could decrease costs and preserve future treatment options.
•Antiretroviral treatment simplification with darunavir/ritonavir (DRVr-M) or lopinavir/ritonavir monotherapy (LPVr-M) has shown good efficacy in patients with sustained virological suppression. However, only DRVr-M demonstrated noninferior efficacy versus triple therapy at 48 weeks whilst LPVr-M only showed noninferior efficacy when reintroduction of NRTI was not considered as failure.
•Nevertheless, data about the efficacy of this strategy in routine clinical practice are still limited, and no direct comparison between DRVr-M and LPVr-M has been performed to date.
•The objective was to assess the long term effectiveness and safety of PI monotherapy as a treatment simplification strategy in routine clinical practice.
We also compared the effectiveness and safety of DRVr and LPVr monotherapy.
•All consecutive patients who had initiated DRVr-M or LPVr-M monotherapy with a HIV-1 RNA load in plasma <50 copies/mL and who had attended at least 1 follow-up visit between November 2003 and June 2012 were identified from a prospectively compiled database.
•In case a patient had received treatment with both DRVr-M or LPVr-M, each regimen was considered separately.
•Effectiveness analyses:
• On-treatment (OT): virological failure (VF) was defined as 2 consecutive HIV-1 RNA >50 copies/mL during exposure to PI monotherapy; or any detectable VL followed by triple therapy switch, including reintroduction of NRTI.
• Switch equals to failure (S=F): failure was defined as any change in monotherapy due to either VF or toxicity. •Primary endpoints:
• Proportion of patients who maintained HIV-1 VL <50 copies/mL.
• Time to VF. The first date with VL >50 copies/mL was used to calculate the time to VF. •Secondary endpoints:
• Proportion of patients who discontinued their treatment for VF and toxicity reasons. • Time to adverse events development.
• Rate of blips (defined as a single determination of HIV-1 RNA between 50 and 200 copies/mL).
• Effectiveness and safety comparisons between DRVr-M and LPVr-M.
•Effectiveness analysis and time to failure were evaluated by proportion estimations and Kaplan-Meier curves respectively. Chi-square or log rank tests were used to detect differences.
RESULTS RESULTS RESULTS
Table 1. Baseline characteristics (n=573 regimens). a
Baseline characteristics:
•We identified a total of 211 and 256 subjects who had initiated DRVr-M and LPVr-M, respectively, with HIV RNA <50 copies/mL.
•51 patients were consecutively switched from LPVr to DRVr and 2 more subjects from DRVr to LPVr.
•Sample comprised 573 monotherapy regimens (262 with DRVr and 311 with LPVr-M).
•Overall, the median (IQR) time of follow-up was 65.7 (30.0-141.8) weeks.
•Median (IQR) time of follow-up for DRV/r and LPV/r-M were 50 (26.3-107.6) and 85.6 (36.9-179.1) weeks, respectively (p<0.001). •Overall, 74.5% of patients of patients with PI monotherapy maintained virological suppression at 192 weeks in routine clinical practice.
•Effectiveness at 192 weeks seems to be similar between DRVr and LPVr-M, according to OT analysis.
•LPVr-M seems to be less effective than DRVr-M in S=F analyses. This could be explained by the higher rates of adverse events leading to treatment discontinuation in subjects on LPVr.
•VL re-suppression is achieved by reintroduction of NRTI in most patients who experienced VF while on monotherapy.
•Prospective studies to confirm these findings are warranted. 
CONCLUSIONS CONCLUSIONS CONCLUSIONS
Effectiveness
Abbreviations: VL, viral load; OT, on-treatment; S=F, switch equals failure.
•Overall, when only patients whose VL was available up to week 192 were considered, 508/573 (88.7%) subjects maintained HIV-1 RNA <50 copies/mL, and 65/573 (11.3%) experienced VF.
•In S=F analysis, 427/573 (74.5%) patients maintained virological suppression at 192 weeks.
•During follow-up, 101 (17.6%) patients experienced blips: 47 (46.5%) were on DRVr-M and 54 (53.5%) were on LPVr-M (p=0.826).
Abbreviations: DRV/r, darunavir/ritonavir; LPV/r, lopinavir/ritonavir; VL, viral load; VF, virological failure
•In OT analysis, 239/262 (91.2%) patients on DRVr-M and 272/311 (87.5%) subjects on LPVr-M maintained virological suppression at 192 weeks (p=0.095).
•Of those subjects who experienced VF, 12/23 (52.2%) patients on DRVr-M and 24/42 (57.1%) on LPVr-M had poor adherence.
•From 23 subjects with VF to DRVr-M, HIV-1 RNA was resuppressed in 20 patients: NRTIs were reintroduced in 11 cases, DRVr-M was maintained in 2 cases, and other ARV drug combinations were used in 7 cases. Self-reported poor adherence was registered in 3 patients who maintained DRVr-M and HIV RNA was not re-suppressed.
•From 42 subjects with VF to LPVr-M, HIV-1 RNA was re-suppressed in 38 patients: NRTIs were reintroduced in 13 cases, switching to DRVr+2 NRTI was done in 9 patients, LPVr-M was maintained in 3 subjects, and other ARV drug combinations were added in 13 cases. Self-reported poor adherence was registered in 3 patients who were not re-suppressed despite NRTI reintroduction, and 1 patient was lost to follow-up.
Abbreviations: VL, viral load; DRV/r, darunavir/ritonavir; LPV/r, lopinavir/ritonavir
•In "S=F" analysis, 221/262 (84.4%) patients on DRVr-M and 206/311 (66.2%) subjects on LPVr-M maintained virological suppression at 192 weeks (p<0.001).
•The mean time to failure was 149.1 (CI 95% 138.2;160.0) weeks for patients on DRVr-M, and 125.7 (CI 95% 116.7;134.7) weeks for patients on LPVr-M.
•Time to failure was significantly shorter in patients on LPVr-M (log rank, p=0.002). •There were significantly less treatment discontinuations due to adverse events in subjects taking DRVr than LPVr-M (7.3 vs 22.8%, respectively, p<0.001).
Safety
•Adverse events leading to treatment discontinuations were mainly dyslipidemia and gastrointestinal side effects. There were no Grade 3-4 adverse events. Poster number: P305
BACKGROUND
Simplification with PI boosted monotherapy may be a useful strategy in terms of reduction of number of drugs and related toxicities as well as of therapy costs
Several trials have demonstrated that this is a safe approach, at least in selected patients, but till now there are no data on the efficacy and toxicity of such simplification regimens in the real world setting
Although in Italy such regimens are considered Ô off labelÕ , there is an increasing number of clinicians who choose this strategy for their patients. Among these, the most frequent boosted PI used is LPV/r, both because of the data available from clinical trials, and because of its large use among Italian HIV infected patients
OBJECTIVE
The main objective was to evaluate the durability of LPV/r-monotherapy (MT) in terms of time to virological rebound (VR), time to discontinuation/intensification or a composite endpoint considering both (=treatment failure). Secondary objectives were:
• to identify factors associated with faster progression to treatment failure • to evaluate changes from baseline in CD4 cell count during follow up • to evaluate changes from baseline in plasma lipids and eGFR during follow-up
PATIENTS AND METHODS
• Study design: prospective observational • Inclusion Criteria:
• Either LPV/r naive or LPV/r experienced HIV infected individuals initiating for the first time LPV/r monotherapy as simplification strategy (after >2 consecutive HIV RNA levels <=50 copies/mL) Patients were either enrolled in the Icona Fundation Study (IFS) or in one of the sites participating in IFS, regardless of whether they met IFS inclusion criteria (being ART-na• ve at presentation)
• PatientsÕ follow--up accrued from the date of starting LPV/r monotherapy to the event of interest (VR, defined using the thresholds of 50 or 200 cp/mL confirmed two times consecutively, or a composite endpoint considering a single VR > 200 cp/mL or discontinuation/intensification). Follow-up of people not experiencing the event was censored at the date of their last available visit/VL measurement.
• Standard survival analysis employing Kaplan-Meier curves and Cox regression analsysis was used.
o CONCLUSIONS o In our Ô real-lifeÕ setting, the KM estimates of remaining with a VL suppressed <=50 copies/mL by 3 years of starting LPV/r-MT, was of 64%. This percentage was >80% when considering only confirmed virological failures o The only factor associated with a reduced risk of treatment failure was having switched from previous LPV/r-including combinations (vs. other type of switches); also, people with higher CD4 count nadir and those who had been with a VL<=50 for longer before switching to LPV/r MT tended to be at lower risk of failure. 
RESULTS
BACKGROUND
OBJECTIVE
CONCLUSIONS
Simplification of antiretroviral therapy (ART) may be an option for virologically suppressed patients for a variety of reasons. Etravirine (ETV) 400 mg qd has good safety profile and retains activity against viruses resistant to nevirapine or efavirenz.
Our results suggest that ETV plus 2NRTI could be a good strategy for simplification in virologically suppressed patients despite previous episodes of VF provided that the GSS to the new regimen is >=1.5 and ETV remains active.
We selected patients who were changed from a protease inhibitor (PI) based regimen to ETV plus two NRTIs while virologically suppressed, but that had presented a former virological failure while on NRTIs +/-NNRTIs. A Genotypic Resistance Test performed during previous virological failure had to be available. Eligible subjects were followed for >= 6 months. Primary endpoint was proportion of patients remaining virologically suppressed using an ITT analysis. The weight of the GRM was analyzed through a genotypic sensitivity score (GSS) that was calculated summing individual antiretroviral scores obtained through Fourteen (10%) of 145 subjects switching to ETV+2NRTIs while virologically suppressed had a documented prior VF and presence of GRM and were included in the analysis. Median (range) number of previous episodes of VF to ART, NRTI-containing regimen, to a NNRTI-containing regimen and to a PI-containing regimen were 4(1-6), 2(1-5), 1(0-2) and 1(0-2) respectively.
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METHODS
Our objective was to evaluate the efficacy of ETV plus two nucleoside reverse transcriptase inhibitors (NRTIs) as a simplification strategy in treatment-experienced virologically suppressed individuals with prior episodes of virological failure (VF) and presence of Genotypic Resistance Mutations (GRM).
Median duration of virological suppression before switching therapy was 22.5 months (1-65). All patients switched from an effective PI-containing regimen (8 LPV/r, 5 ATV/r and 1 DRV/r) to a qd regimen with ETV 400 mg plus Truvada® (n=12) or Kivexa® (2).
Eleven out of fourteen patients (79%) remained virologically suppressed at >=6 months. All of them had a GSS >1.5 to the new regimen and none had resistance to Etravirine.
Conversely 3/14 (21%) developed a VF at 1, 3 and 6 months respectively. Two of them had a GSS 1.5 to the new regimen and intermediate resistance to ETV (Y181C). The third one had a GSS 1.75. All these 3 patients had a former VF to a nevirapine containing regimen. No side effects were reported.
